"These trends threaten to shortchange the American biotech ecosystem. Every dollar spent to license compounds from China is a dollar diverted from innovation corridors such as South San Francisco and North Carolina’s Research Triangle."

"To win the biotechnology race, we need to start by getting our own house in order. Currently, the U.S. government has no cohesive, intentional biotechnology strategy, while China is gaining ground thanks to its aggressive and carefully coordinated state-led initiatives."

"If the United States instead imports other countries' price-control schemes, global medical R&D will collapse, with no country but China likely to pick up the slack."

“At a time when China is becoming an increasingly fierce competitor in this industry, policymakers should stop approaching America’s biopharmaceutical industry with price controls and tariffs and instead start supporting it in two key ways: 1. by insisting that other countries pay their fair share for medicines—thereby raising the floor instead of racing to the bottom; and 2. by investing in public-private partnerships to develop the technological innovations that can help companies cost-competitively manufacture medicines in the United States (generic and innovative alike).”

“If the U.S. continues to hamstring its own industry, we will risk ceding the future of medicine to China, our access to medical innovations, and a robust industrial research and manufacturing base with high-paying jobs that follow.”

"In the face of this onslaught, no single action will be enough; there is no silver bullet that will singlehandedly delay China’s progress by a decade or secure U.S. dominance for a generation. Rather, the U.S. government must aggressively deploy all the tools at its disposal to preserve American biotechnology leadership."

“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s biotechnology leadership.”

"Harnessing our innovative strength will require prioritization. We must treat biological data as geopolitically important, as China already does. We must ensure that researchers have the tools they need to continue conducting the best research in the United States. And we must emphasize safety, security, and responsibility—so that the norms and standards of innovation align with American values and interests."

"China is no longer a market of “me-too” drugs. Increasingly, the country is home to first-in-class or globally competitive therapies, particularly in areas like oncology, autoimmune disease, and cell therapy. What’s more, the price point is compelling – some Chinese-developed assets are “30% off” typical market valuations, creating significant upside for early backers."

“We need to think about the cost of our research and development activities and how to do it cheaper. We have to be competitive with what China is doing.”

“The current system works by ensuring broad patient access to medicine while enabling companies to reinvest in research and development. Drastic changes such as MFN pricing would upend this balance and threaten job creation and investment in states like Georgia.”

“America leads the world in drug development because we reward risk-taking. MFN would reverse that -- cutting off the lifeblood of future cures and weakening our global leadership. We urge policymakers to reject MFN and pursue smarter reforms that improve access without sacrificing innovation. The future of medicine depends on it.”

"China’s approach to recruiting and retaining foreign talent stands in stark contrast. The Chinese government invests vast sums of money to attract international students and workers, using state-of-the-art, multi-million-dollar research facilities and large cash incentives to lure them to China."